Dr. Italo Linfante, MD

Dr. Linfante practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Linfante's NPI, 1073549705, was assigned on June 24, 2006. Dr. Linfante graduated from Sapienza University of Rome in 1987. Dr. Linfante holds Florida license ME90425.

Dr. Linfante's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Linfante's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. The medical group on file is Baptist Health Medical Group. Dmand AI also links Dr. Linfante to 1 more breast imaging center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Linfante practices, 3 sites in all. Vendor and product names are available with a free account.

Neuroradiology is Dr. Linfante's primary specialty in the NPI Registry, under taxonomy code 2085N0700X. Dr. Linfante is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Linfante's licenses on file in 2 states: Florida and Massachusetts.

CMS data shows 501 Medicare services from Dr. Linfante across 15 procedure codes in 2024, for 136 Medicare patients. Medicare paid $94,440 for them.

CMS counts 136 Medicare patients who saw Dr. Linfante in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Linfante's median patient age at 70, with 66% women.

In 2021, Dr. Linfante wrote 75 Medicare Part D claims. They cover 2 drugs, with $24,897 in total drug cost. In 2020, CMS named 58 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Linfante for performance year 2024, reported through an alternative payment model (APM). Dr. Linfante accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Linfante as offering telehealth.

Dmand AI links 142 papers to Dr. Linfante, published from 2005 to 2025. 2016 was the busiest year, with 10. The most frequent topics are Stroke, Brain Ischemia and Cerebral Angiography. Dr. Linfante has published most often in J Neurointerv Surg. Dr. Linfante's most frequent co-authors are Guilherme Dabus, MD, Ajay K. Wakhloo, MD and Andrew Rathnasamy Xavier, MD.

Dmand AI links Dr. Linfante to 1 clinical trial. Conditions studied include Hematoma, Subdural, Intracranial and Hematoma, Subdural, Chronic. Open Payments lists research payments to Dr. Linfante that name 1 trial.

CMS Open Payments shows 472 general payments to Dr. Linfante from 41 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Stryker Corporation paid the most, $141,190. It also lists 15 research payments totaling $33,125 from 2022 to 2025, naming 1 clinical trial.

Dr. Linfante graduated from Sapienza University of Rome in 1987.

Dr. Linfante is in network with 8 carriers, including Excellus BlueCross BlueShield, United Healthcare and Cigna. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.